|
WO2009085237A2
|
|
Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
|
|
WO2009032256A2
|
|
Apc activators in combination with a cytokine-secreting cell and methods of use thereof
|
|
WO2009014708A2
|
|
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
WO2008124102A2
|
|
Ara-c in combination with a cytokine-secreting cell and use thereof
|
|
WO2008121307A2
|
|
Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer
|
|
US2008118470A1
|
|
Oncolytic adenoviral vectors encoding GM-CSF
|
|
WO2008013989A2
|
|
Methods and compositions for identifying a cellular immune response against prostate cancer
|
|
US2007292922A1
|
|
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
|
US2007231298A1
|
|
Cytokine-expressing cancer immunotherapy combinations
|
|
EP1877429A2
|
|
Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
|
|
WO2006110240A2
|
|
Gene transfer with adenoviruses having modified fiber proteins
|
|
WO2006093924A1
|
|
Formulations for therapeutic viruses having enhanced storage stability
|
|
CN101163794A
|
|
Formulations for therapeutic viruses having enhanced storage stability
|
|
CA2577989A1
|
|
Cytokine-expressing cellular vaccines for treatment of prostate cancer
|
|
CN101068933A
|
|
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
|
WO2006026331A2
|
|
Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
|
|
WO2006020802A2
|
|
Devices for introducing a gas into a liquid and methods of using the same
|
|
WO2006012393A2
|
|
Addition of transgenes into adenoviral vectors
|
|
CN101035901A
|
|
Addition of transgenes into adenoviral vectors
|
|
EP1765846A2
|
|
Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
|
